Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Amphetamine-Related Disorders: early-phase trial registry

1 of 6 indexed Amphetamine-Related Disorders trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 1 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Amphetamine-Related Disorders: 6 US clinical trials tracked, 1 recruiting.

Amphetamine-Related Disorders is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute on Drug Abuse (NIDA), running 2 of these trials.

Enrollment posture brief

Registry condition amphetamine-related-disorders

OPEN 1 | RECR 17% | LATE 0 | EARLY 6 | RANK #2866 | SPON 2

Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Amphetamine-Related Diso (th…17%
Open-enrollment share among volume-matched conditions near Amphetamine-Related Disorders

Amphetamine-Related Disorders lists 1 open slots (17% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Amphetamine-Related Disorders on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Amphetamine-Related Disorders is recruiting below its size-band peers.

    1 of 6 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Amphetamine-Related Disorders research.

    National Institute on Drug Abuse (NIDA) accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Amphetamine-Related Disorders trials plan to enrol fewer than 100 people.

    Median target enrolment is 89 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.

  4. Amphetamine-Related Disorders research is mostly interventional.

    6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 24

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4

Named interventions

Most-linked intervention names on Amphetamine-Related Disorders records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Tyrosine Behavioral
1 trials
CM Behavioral
1 trials
NRP104 Drug
1 trials
Treatment-as-usual Behavioral
1 trials
Naltrexone Drug
1 trials
Bupropion Drug
1 trials
Truvada Drug
1 trials
Psilocybin Drug
1 trials

US sites by state

Facility locations filed on Amphetamine-Related Disorders trials. A trial with sites in several states counts in each.

California 4 trials
Washington 1 trials
Missouri 1 trials
Maryland 1 trials
Iowa 1 trials
Hawaii 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Amphetamine-Related Disorders page

6 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Amphetamine-Related Disorders condition card totals 6 registered trials; most-linked intervention Tyrosine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.